Clinical Trial Update: Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating dasatinib in combination with bevacizumab for recurrent or progressive high-grade glioma or glioblastoma multiforme has completed with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme
• High-grade Glioma

Drugs mentioned

• Bevacizumab (bevacizumab)
• DASATINIB (Dasatinib)

Snippet

Sponsor: Alliance for Clinical Trials in Oncology | Conditions: Glioblastoma Multiforme | Phase 2 | Status: COMPLETED | Results posted: 2017-06-27